90.77% of Vertex Pharmaceuticals' stock owned by institutional investors, despite analyst downgrades and insider selling.

Vertex Pharmaceuticals' institutional investment decreased slightly in Q3, but 90.77% of the company's stock is still owned by institutional investors and hedge funds. Most analysts rate Vertex as a "buy" or "strong-buy," with average target price at $417.27. Despite some analysts downgrading the stock and recent insider selling, institutional investors continue to hold strong interest in the company.

March 11, 2024
4 Articles